Tag: Circulating tumor DNA (ctDNA)

AI partners with liquid biopsy for ‘robust’ identification of women with ovarian cancer

April 10, 2024 9:00 am

by Josh Friedman

Key takeaways:

  • AI-analyzed fragmentomes and protein biomarkers better distinguished women with ovarian cancer in screening.
  • Liquid biopsy assay outperformed CA125 analysis alone.

An artificial intelligence-driven algorithm used a novel liquid biopsy assay to differentiate women with ovarian … Read more

ctDNA Offers Potential Biomarker for PARP Inhibitor Maintenance Therapy in Epithelial Ovarian Cancer

March 20, 2024 9:00 am

Clearity’s Perspective: At the SGO meeting several presentations described how circulating tumor DNA (ctDNA) may be a new, personalized, sensitive tool to help evaluate treatment de-escalation, monitor minimal residual disease (MRD), and track treatment response in ovarian cancer. The application … Read more